Segment and Geographic Information - Reconciliation of Reportable Segment Operating Income (Loss) to Corresponding Consolidated Amounts (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Segment Reporting Information [Line Items]
Total revenue	$ 159,134	$ 148,401	$ 313,451	$ 326,767
Amortization of other intangible assets	13,000	12,400	25,500	24,000
Purchase accounting impact on inventory		2,912		5,781
Transformation costs	4,446	10	4,487	(55)
Restructuring charges	7,344	1,499	8,464	2,961
Impairment of goodwill and intangible assets	115,975		115,975
Provisions			3,231	2,961
Contingent consideration - fair value adjustments		(17,145)		(17,145)
Merger and acquisition costs and costs related to share repurchase	426	19	4,747	11,857
Total operating loss	(146,955)	(12,977)	(173,632)	(40,662)
Interest income, net	9,565	10,394	19,646	21,059
Other income (expense), net	250	(2,668)	932	(1,523)
Loss before income taxes	(137,140)	(5,251)	(153,054)	(21,126)
Completed Technology
Segment Reporting Information [Line Items]
Amortization of other intangible assets	6,373	4,901	12,000	9,070
Intangible Assets Excluding Completed Technology
Segment Reporting Information [Line Items]
Amortization of other intangible assets	6,654	7,509	13,516	14,882
Sample Management Solutions
Segment Reporting Information [Line Items]
Total revenue	74,137	71,043	153,142	146,498
Multiomics
Segment Reporting Information [Line Items]
Total revenue	62,218	62,236	124,938	123,325
B Medical Systems
Segment Reporting Information [Line Items]
Total revenue	22,779	15,122	35,371	56,944
Operating Segments
Segment Reporting Information [Line Items]
Total operating loss	(5,686)	(13,254)	(14,402)	(13,213)
Operating Segments | Revision of Prior Period, Adjustment
Segment Reporting Information [Line Items]
Total operating loss		8,000		16,500
Operating Segments | Sample Management Solutions
Segment Reporting Information [Line Items]
Total operating loss	(1,567)	(6,076)	(2,423)	(9,074)
Operating Segments | Multiomics
Segment Reporting Information [Line Items]
Total operating loss	(2,966)	(3,810)	(6,417)	(7,075)
Operating Segments | B Medical Systems
Segment Reporting Information [Line Items]
Total operating loss	(1,153)	(3,367)	(5,562)	2,936
Corporate, Non-Segment
Segment Reporting Information [Line Items]
Other unallocated corporate expense	$ 51	$ 18	$ 41	$ 98